Objective: To assess the efficacy of silodosin as second-line a-blocker monotherapy in patients with lower urinary tract symptoms as a result of benign prostatic hyperplasia. Methods: Men who were given an a-blocker other than silodosin for ≥8 weeks, aged ≥50 years, had a total International Prostate Symptom Score ≥13 and quality of life index ≥4 were enrolled. After treatment with 8 mg/day silodosin for 8 weeks, symptoms and treatment satisfaction were assessed. If the patients still complained and hoped for readministration of the first-line a-blocker, the previous medication was administered again for 8 weeks in the case of persisting symptoms, and efficacy was again evaluated. Results: A total of 73 patients were enrolled and analyzed at 8 weeks. Silodosin administration significantly improved the International Prostate Symptom Score and Overactive Bladder Symptom Score. The quality of life index was improved by at least 1 point in 49.3% patients, and its mean change was significantly greater in the group with previous naftopidil treatment than in those with tamsulosin. A total of 59 patients hoped to continue silodosin, and 13 requested administration of the first-line a-blocker. Previously taking naftopidil and having a shorter duration of prior a-blocker treatment at baseline were associated with silodosin continuation. Although prior a-blocker readministration in the 13 patients did not show significant efficacy, six preferred to continue the previous a-blocker. Conclusions: Silodosin represents an effective second-line a-blocker monotherapy, even in those who still have moderate lower urinary tract symptoms.
Introduction
According to the guidelines for MLUTS associated with BPH or BOO, one of the standard first-line medications is a-blocker monotherapy. 1 In addition, if its efficacy is insufficient or moderate symptoms still remain, drug combination therapy considering prostatic volume and/ or concomitant OAB symptoms is recommended, as is conversion to prostatic surgery. However, in daily clinical practice, changing the a-blocker is also selected as one of the treatment choices. As LUTS are progressive with aging and associated with impaired QOL, not only improvement of the objective parameters, but also the patient's subjective satisfaction with the treatment is an important factor in the decision-making process. Furthermore, dosage differences, the number of administrations and adverse reactions to each drug greatly affect the patient's treatment satisfaction.
Silodosin, which is an a-blocker with greater selectivity for a1A-AR than other drugs, has shown efficacy for MLUTS associated with BPH. 2 This higher a1A-AR selectivity suggests that silodosin might be a promising second-line drug in BPH patients for whom taking a previous a-blocker had insufficient efficacy. In contrast, silodosin also has well-known adverse effects, such as ejaculation disorders, and needs to be taken twice daily. A previous study showed that not a negligible number of patients worried about such disorders, 3 and some patients abandoned taking the medicine because of these factors. 4 In the present study, we evaluated the efficacy and safety of silodosin as second-line a-blocker treatment in LUTS/BPH patients. In particular, we targeted patients with poor responses and lower satisfaction with the previous a-blocker medication, and focused on improvements of not only the parameters in questionnaires, but also each patient's subjective treatment satisfaction. Furthermore, if they felt silodosin was still unsatisfactory and preferred the previous drug, we readministered it, evaluated its efficacy and investigated their backgrounds as well as the reasons why they wanted to change the drug.
Methods
This was a multicenter, non-randomized, prospective, observational study carried out in Hokkaido, Japan. Study protocol approval was obtained from the institutional review board of Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan (NO25-63). All participants provided informed consent for this study. We enrolled participants who had LUTS associated with BPH and received a-blocker monotherapy other than silodosin for ≥8 weeks. The inclusion criteria were: age ≥50 years, a total IPSS ≥13, IPSS-QOL index ≥4 and hope of continuation of a-blocker monotherapy. In contrast, the following patients were excluded: those who were previously diagnosed with neurogenic bladder; those with urinary tract infection; those having prostate cancer or urothelial carcinoma; those taking concomitant drugs, such as anticholinergic agents, beta 3-adrenoceptor agonists and 5-a reductase inhibitors; those who had received prostatic operation; and those judged as inappropriate to enroll in the study by physicians.
First of all, we selected patients who matched the criteria, and questioned them as follows: "There are other drugs having similar efficacy to the present drug that you are taking. If you are not satisfied with the current LUTS and medication, but want to continue drug therapy, do you want to switch to another drug?" Then, if they agreed to enroll in the study, they started taking silodosin 4 mg twice-daily (total 8 mg/ day) without washout of the previous a-blocker. After 8 weeks, the changes of the IPSS, QOL and OABSS were evaluated as parameters for symptom improvement. In addition, we investigated adverse drug reactions, and changing subjective symptoms and satisfaction with the current medication by asking them a simple original question (Appendix S1). If they agreed to continue medication with silodosin, the study was finished. In contrast, if they were still dissatisfied with their present condition, we confirmed whether they hoped for readministration of the former medication and, if so, the former medication was administered again for a further 8 weeks. Finally, at 16 weeks after enrollment, we re-evaluated the patients using the same approach as at 8 weeks.
In the present study, we investigated the age at study participation and the details of previous medication as the patients' backgrounds. We evaluated prostate volume and carried out uroflowmetry and/or measured the post-void residual urine volume at each evaluation period to the degree possible, because we focused on the changes in the patients' subjective symptoms. Data are shown as the mean AE standard deviation. Intragroup and intergroup differences in the parameters were analyzed using paired and unpaired t-tests, respectively. A P-value of <0.05 was considered statistically significant.
Results

Patient characteristics
A total of 117 patients provided informed consent to participate in this study, but 17 withdrew because of protocol deviance. Thus, 100 patients were included and started receiving silodosin. During the 8 weeks of treatment, 12 patients withdrew from the medication as a result of adverse drug reactions (4, diarrhea/soft stool; 3, ejaculation failure; 2, nausea; 1, vertigo; 1, dry mouth; 1, nasal congestion), four for other reasons and two received prostatic surgery. In addition, nine patients could not evaluate drug efficacy at 8 weeks. Therefore, there were 73 patients as participants for full analysis of the efficacy. Their baseline characteristics are presented in Table 1 . Their mean age was 72.3 years. Of the 73 patients, 40 took tamsulosin 0.2 mg/day and 33 naftopidil (1, 25 mg/day; 16, 50 mg/day; 16, 75 mg/day) as the previous a-blocker, and the mean duration of taking these drugs was 30.3 months.
Effects of silodosin for 8 weeks
The total IPSS significantly improved from 19.1 AE 5.3 to 14.1 AE 6.4 (P < 0.001) after silodosin administration, and IPSS storage and voiding subscores were also significantly improved (Table 1) . A total of 37 patients (50.7%) had total IPSS improvement of >25% from baseline. In addition, the QOL index was improved by at least 1 point in 36 patients (49.3%), and its mean change was 0.79. The total OABSS was also significantly improved from 5.8 AE 3.0 to 4.9 AE 2.8 (P = 0.009), but only the OABSS-Q2 (night-time micturition) showed significant improvement (P < 0.001) among the individual parameters.
Efficacy comparison by type of previous a-blocker
We evaluated whether the kind of previous a-blocker affected the efficacy of silodosin (Table 2) . At baseline, IPSS-Q1 (incomplete emptying) and Q4 (urgency) were significantly worse in the tamsulosin group than in the naftopidil group (P = 0.003 and 0.016, respectively). After 8 weeks, the mean changes in IPSS-Q2 (frequency) and Q6 (straining) were significantly improved only in the naftopidil group, but there was no significant difference in the mean change of the total IPSS between the groups (tamsulosin À3.85, naftopidil À6.30, P = 0.129). The mean change in the OABSS did not show a significant difference either. Nevertheless, the QOL index was significantly improved in the naftopidil group (tamsulosin À0.50, naftopidil À1.15, P = 0.046). The results of the original questionnaires are summarized in Table 3 . After silodosin administration for 8 weeks, 39 patients (53.4%) answered that their symptoms were improved. In contrast, 10 of the 30 patients (41.1%) who responded that there was no change in their symptoms preferred the previous a-blocker medication. All four patients (5.4%) who felt that their symptoms had deteriorated converted to the previous ablocker again. Finally, 59 patients were satisfied with their present condition and hoped to continue silodosin (Sil-cont group), but the remaining 14 requested readministration of the previous a-blocker (12, tamsulosin; 2, naftopidil). Of them, one could not be evaluated in detail after naftopidil readministration. Therefore, the final full analysis readministration group consisted of 13 patients (Re-ad group).
When we compared the backgrounds of the patients in the Sil-cont and Re-ad groups at baseline (0 weeks), the patients in the Re-ad group had a significantly lower rate of previous naftopidil administration than those in the Sil-cont group (P = 0.004), and had a significantly longer treatment duration with the previous a-blocker (P = 0.008). However, other parameters were not significantly different between the groups (Table 4 ). When we used the IPSS and OABSS to evaluate whether the efficacy of silodosin at 8 weeks affected the patients' drug preferences, we found that the mean changes in the total IPSS (P = 0.042), IPSS-Q2 (P = 0.009) and QOL index (P = 0.025) were significantly improved in the Sil-cont group compared with the Re-ad group. 
Effects of readministration of previous a-blocker for a further 8 weeks
In the 13 patients in the Re-ad group, readministration of the previous a-blocker for a further 8 weeks did not result in significant changes in the IPSS and OABSS, although IPSS-Q1 (incomplete emptying) and Q7 (nocturia) were still significantly improved compared with baseline (0 week; P = 0.039 and 0.002, respectively). With regard to the treatment efficacy and satisfaction at 16 weeks, four patients answered that their symptoms were improved after previous a-blocker readministration. Furthermore, six patients hoped to continue the previous drug, two preferred silodosin and five felt that the efficacy of the drugs was the same. Finally, we investigated in detail the reasons why some patients preferred the previous a-blocker after silodosin administration. Most of them felt that the efficacy of silodosin was not sufficient (eight patients). In addition, specific adverse reactions to silodosin, such as diarrhea/soft stool (three patients), dry mouth (one patient) and erectile dysfunction (one patient), were the reasons that they abandoned continuation. Interestingly, cost (two patients) and difficulty in taking the drug twice daily (five patients) were also reasons for selecting the previous a-blocker.
Discussion
We clarified that silodosin, which has greater selectivity for a1A-AR, is a promising second-line a-blocker monotherapy for patients with LUTS/BPH. In particular, even for those who had moderate or severe LUTS and complained about their QOL (IPSS-QOL index ≥4), silodosin administration for 8 weeks showed excellent efficacy. In addition, administration of naftopidil as the previous a-blocker was associated with the efficacy of and preference for silodosin. Furthermore, the patients who had a short duration of taking a previous a-blocker had a tendency to select silodosin continuation. In contrast, we found that not only specific adverse reactions as a result of silodosin, but also the drug cost and the number of administrations of this drug were factors affecting the drug preferences of the patients. As there have been very few data like those in the present study, we believe this is a very informative study for physicians and patients. The results of the present study will help us select patients who are ideal for sequential a-blocker medication in real-life clinical practice.
The efficacy of a-blockers for patients with LUTS/BPH is clear, and we can now choose among the drugs alfuzosin, doxazosin, naftopidil, silodosin, tamsulosin and terazosin. The treatment efficacy of each drug is thought to be similar for improvement of the IPSS and maximum urinary flow rate. The results of a meta-analysis suggest that these a-blockers objectively improve urinary voiding function in patients with LUTS/BOO. 5 Another meta-analysis has clarified that tamsulosin 0.2 mg has similar efficacy and fewer adverse events than other a-blockers as an initial treatment for men with LUTS. 6 Therefore, one of the important issues in a-blocker selection for patients with male LUTS/BPH is how to maintain their QOL as long as possible. Among Japanese LUTS/ BPH patients, the long-term persistency rate of each a-blocker is relatively low. The 5-year persistency for tamsulosin is 30.4%, 7 and the 3-and 4-year rates for naftopidil are 21.4% and 19%, respectively. 8, 9 In the case of silodosin, one study showed that the 4-year persistency rate was 35.8%, 10 and another that the 6-year rate was 25%. 11 According to the present prospective observational study, one of the reasons for withdrawal was unsatisfactory effects in 28.8% of patients. Prostatic surgery was carried out in 70% of these patients. 11 It is natural that surgical treatment should be recommended in such a situation, but conversion to other ablockers is also a promising option. One hypothesis is that the expression levels of a1-AR subtypes (a1A, B and D) in the prostate differ among patients, and individual differences in the genetic backgrounds of patients with BPH might be associated with variations in their responses to subtype-selective a-blocker. 12 In the present study, we included patients who continued a-blocker treatment for approximately 2.5 years, but complained about their QOL (IPSS-QOL index ≥4). In other words, these patients might not be suitable or be unfit for a-blocker monotherapy. However, silodosin administration could improve the IPSS (mean change 4.95), OABSS (mean change 0.89) and subjective patient satisfaction (53.4% were satisfied). In particular, those who took naftopidil (which has greater selectivity for a1D-AR) as their previous medication or had a relatively short duration of a-blocker monotherapy could profit from silodosin. Therefore, we have to ensure that patients are eligible for sequential a-blocker treatment to avoid unnecessary medication.
Although the treatment efficacies of the various a-blockers are thought to be similar, the types and frequencies of drugspecific adverse reactions are different. In addition, the frequencies of adverse reactions also differ among individuals. In the present study, 12 patients withdrew from medication as a result of adverse drug reactions during 8 weeks. Thereafter, 13 patients chose readministration of their previous medications. Interestingly, even though 8-week readministration led to deterioration of their symptoms, as evaluated by questionnaire, some patients hoped to continue taking the previous drug at the study end-point. The reasons why they preferred the previous medication were not only drug efficacy or adverse reactions, but also the drug dosage and cost. Therefore, we have to keep in mind that patients have selection criteria for medication other than expectation of its efficacy, and that these criteria considerably affect their subjective treatment satisfaction and adherence.
The limitations of the present study also need to be addressed. Our study protocol was open label, and the inclusion targets were those who had strong dissatisfaction with their present condition. In addition, a relatively large number of patients who were initially enrolled were excluded from the full analysis set. Furthermore, we evaluated not all ablockers as control drugs, but only silodosin administration for second-line medication. Based on the hypothesis of diversity of AR subtypes in patients with LUTS/BPH, there is a possibility that some subsets of patients would respond better to naftopidil than to silodosin after the initial treatment of tamsulosin. Taken all together, we cannot clarify the pure/true efficacy of silodosin itself. However, we carried out a protocol in which patients themselves could decide study continuation and try a previous drug again with discretion if they felt dissatisfied with silodosin treatment. Thus, we believe that this study clarified an effect and limitation of silodosin as second-line treatment for LUTS/BPH in the clinical setting.
In conclusion, silodosin was effective for improvement of subjective symptoms and provided satisfaction as one of the options in second-line a-blocker treatment for patients with moderate or severe LUTS and poor QOL.
